

Aurigene Pharma launches new database for accelerated hit identification

02 September 2025 | News

Providing researchers with a powerful tool to identify early hits in drug discovery programmes



Bengaluru-based Aurigene Pharmaceutical Services, a leading Contract Research, Development and Manufacturing Organization (CRDMO), has announced the launch of the Aurigene Database (Aurigene DB – Virtual Library) on the CHESE (Chemical Exploration Engine for Similarity & Substructure Exploration) platform.

This new resource enables compound similarity and substructure searches, providing researchers with a powerful tool to identify early hits in drug discovery programmes.

This initiative marks a significant milestone for Aurigene's scientific community, reflecting both innovation and self-reliance. The achievement brings immense pride to the team, who have worked relentlessly for over two years to make this vision a reality.

"Our vision with the Aurigene Database is to empower researchers with seamless access to high-quality chemical space, while reducing dependency on external vendors for compound procurement in hit identification," said Shahadat Ahmed, PhD, Head of Integrated Drug Discovery at Aurigene Pharmaceutical Services. "This launch exemplifies our commitment to innovation and efficiency in supporting drug discovery programmes worldwide through AIDD, IDD and IND enabling services"

Key Highlights of the Aurigene Database on CHEESE:

- Powerful Search Capabilities Conduct compound similarity and substructure searches.
- Streamlined Hit Identification Quickly identify focused sets of compounds for early discovery.
- Integrated Business Model Researchers can reach out to Aurigene services for synthesis support of identified hits.
- Independence from External Vendors Enabling in-house compound accessibility and reducing procurement hurdles.